Guess which ASX 200 share is up 7% after smashing FY24 guidance

This growing company has outperformed expectations in FY 2024 with another impressive 12 months.

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is roaring higher on Tuesday morning.

At the time of writing, the ASX 200 share is up 7% to $25.79.

Why is this ASX 200 share jumping?

Investors have been buying the company's shares this morning after it released an update on its performance in FY 2024.

According to the release, fourth quarter unaudited revenue came in at approximately US$142 million (AU$218 million). This represents an increase of 46% over the prior year corresponding quarter and a 5% lift quarter-over-quarter.

Telix's revenue is currently generated predominantly from sales of Illuccix, its diagnostic radiopharmaceutical for prostate cancer PET2 imaging.

In light of this strong finish to the year, the ASX 200 share has outperformed its guidance for FY 2024.

It revealed that total unaudited full year revenue is up 55% year on year to approximately US$517 million (AU$783 million). This compares to its guidance range of US$490 million to US$510 million for the year.

Another positive is that the therapeutic and diagnostic radiopharmaceuticals company's investment into research and development (R&D) remains in line with guidance and is being funded by earnings generated from product sales.

Management commentary

The ASX 200 share's managing director and group chief executive officer, Dr. Christian Behrenbruch, was pleased with the company's performance in the fourth quarter. He said:

This has been another great quarter of commercial performance. Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. Boosting our balance sheet and the Nasdaq listing were major corporate milestones. The acquisition of FAP-targeting assets is a major addition to our superb product pipeline.

We are well-positioned for significant expansion, including planned launches of multiple imaging products in key markets and advancing late-stage therapeutic assets into pivotal trials. 2025 is shaping up to be transformative year for Telix.

Those late-stage therapeutic assets include its glioblastoma therapy candidate, TLX101. Based on positive feedback from its meeting with the US FDA, Telix is planning to move forward with an investigational new drug (IND) submission in the first half of 2025.

In addition, it will be progressing its kidney cancer therapy candidate, TLX250, and its prostate cancer therapy candidate, TLX591.

Telix also advised that intends to provide its FY 2025 guidance when it reports its audited FY 2024 results on 20 February 2025.

Following today's gain, the Telix share price is now up 140% over the past 12 months.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Did this biotech company deliver the goods for investors? Let's see what a $1,000 investment would be worth.

Read more »